Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 12/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.49 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3295635 | 0.85 | PKM (0.55) | HPGDTSHRALDH1A1KDM4EPOLB | |
| SCHEMBL29632673 | 0.80 | HPGD (0.56) | HPGDTSHRALDH1A1GRIA3GRIA4 | |
| SCHEMBL34463093 | 0.79 | HPGD (0.58) | HPGDTSHRALDH1A1RECQLGRIA3 | |
| SCHEMBL14872336 | 0.79 | PROKR1 (0.63) | HPGDTSHRALDH1A1GRIA3GRIA4 | |
| SCHEMBL14858253 | 0.79 | HPGD (0.62) | HPGDALDH1A1GRIA3GRIA4KDM4E | |
| SCHEMBL939096 | 0.79 | PROKR1 (0.63) | HPGDALDH1A1GRIA3GRIA4KDM4E | |
| SCHEMBL3294559 | 0.78 | MEN1 (0.54) | POLB | |
| SCHEMBL30667713 | 0.78 | PROKR1 (0.61) | HPGDTSHRALDH1A1RECQLGRIA3 | |
| SCHEMBL1859158 | 0.78 | PROKR1 (0.61) | HPGDTSHRALDH1A1RECQLGRIA3 | |
| SCHEMBL5338061 | 0.78 | HPGD (0.65) | HPGDTSHRALDH1A1RECQLGRIA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080113983-A1 | Nicotinic Acetylcholine Receptor Ligands | ASTRAZENECA AB (SE) | 2008-05-15 | — | — | US | disclosed |
| US-20080113983-A1 | Nicotinic Acetylcholine Receptor Ligands | ASTRAZENECA AB (SE) | 2008-05-15 | — | — | US | disclosed |
| US-20080113983-A1 | Nicotinic Acetylcholine Receptor Ligands | ASTRAZENECA AB (SE) | 2008-05-15 | — | — | US | disclosed |
| EP-1831231-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | AstraZeneca AB (SE) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006065209-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113983-A1 | Nicotinic Acetylcholine Receptor Ligands | CHRNA1, CHRNA2, CHRNB1 | HPGD 1807/4885TSHR 205/4885ALDH1A1 577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.